VIA EDGAR
August 20, 2025
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Candel Therapeutics, Inc. |
Acceleration Request for Registration Statement on Form S-3
Filed August 14, 2025
File No. 333-289595
Ladies and Gentlemen,
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Candel Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to August 22, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Finn Murphy at (212) 459-7257.
If you have any questions regarding this request, please contact William D. Collins of Goodwin Procter LLP at (617) 570-1447 or Finn Murphy at (212) 459-7257.
| Sincerely, |
| CANDEL THERAPEUTICS, INC. |
| /s/ Paul Peter Tak |
| Paul Peter Tak, M.D., Ph.D., FMedSci |
| President and Chief Executive Officer |
| cc: | Charles Schoch, Candel Therapeutics, Inc. |
William D. Collins, Esq., Goodwin Procter LLP
Finnbarr D. Murphy, Esq., Goodwin Procter LLP